PRovisional versus Focal OSTial Stenting for Isolated Ostial Disease Occurring in Coronary Bifurcations (The PROST Trial)–Rationale and Design
Heart, Lung and Circulation · 2026-11
DOI: 10.1016/j.hlc.2026.09.010 ↗Kurz gefasst
Fachartikel in der Zeitschrift Heart, Lung and Circulation, 2026-11. Verfasst von Avedis Ekmejian und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Royal North Shore Hospital, Sydney, NSW, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, …. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
BACKGROUND: Isolated branch ostial coronary bifurcation lesions (Medina 0,1,0 and 0,0,1) remain one of the least studied lesion subsets in percutaneous coronary intervention (PCI). Two techniques, provisional stenting and focal ostial stenting, are commonly used in clinical practice. However, no randomised controlled trial has directly compared these treatment approaches. METHOD: The PRovisional vs Precision OSTial Stenting (PROST) trial is a prospective, multicentre, open-label, randomised controlled trial comparing provisional stenting with precision focal ostial stenting in patients undergoing PCI for isolated branch ostial coronary bifurcation lesions. A total of 274 patients will be randomised in a 1:1 ratio across participating Australasian centres. The trial is embedded within the Australasian Bifurcation Coronary Registry and incorporates mandatory intravascular imaging guidance, independent angiographic core laboratory assessment, and blinded clinical event adjudication. The primary endpoint is target lesion failure at 24 months, defined according to Bifurcation Academic Research Consortium criteria. CONCLUSIONS: To our knowledge, the PROST trial is the first randomised study evaluating provisional versus precision focal ostial stenting for isolated branch ostial coronary bifurcation lesions. Its findings will address an important evidence gap and have the potential to inform future clinical practice and guideline recommendations.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiology, Royal North Shore Hospital, Sydney, NSW, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia; Heart Research Australia, Sydney, NSW, Australia. Electroni…
- Department of Cardiology, Royal North Shore Hospital, Sydney, NSW, Australia.
- Department of Cardiology, Concord Repatriation General Hospital, Sydney, NSW, Australia.
- Department of Cardiology, Box Hill Hospital, Eastern Health, Melbourne, Vic, Australia.
- Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia; Department of Cardiology, Royal Prince Alfred Hospital, Sydney, NSW, Australia.
- Department of Cardiology, Nepean Hospital, Sydney, NSW, Australia.
Zitieren
APA
Ekmejian, A., Collins, N., Ada, C., Chandrasekhar, J., Jain, P., Hallani, H., Lee, A., Arunothayaraj, S., Lo, S., Al Mukhtar, O., Biswas, S., Adams, H., & Bhindi, R. (2026). PRovisional versus Focal OSTial Stenting for Isolated Ostial Disease Occurring in Coronary Bifurcations (The PROST Trial)–Rationale and Design. Heart, Lung and Circulation. https://doi.org/10.1016/j.hlc.2026.09.010
Vancouver
Ekmejian A, Collins N, Ada C, Chandrasekhar J, Jain P, Hallani H, et al. PRovisional versus Focal OSTial Stenting for Isolated Ostial Disease Occurring in Coronary Bifurcations (The PROST Trial)–Rationale and Design. Heart, Lung and Circulation. 2026. doi:10.1016/j.hlc.2026.09.010
BibTeX
@article{Ekmejian2026,
author = {Ekmejian, Avedis and Collins, Nicholas and Ada, Cuneyt and Chandrasekhar, Jaya and Jain, Pankaj and Hallani, Hisham and Lee, Astin and Arunothayaraj, Sandeep and Lo, Sidney and Al Mukhtar, Omar and Biswas, Sinjini and Adams, Heath and Bhindi, Ravinay},
title = {PRovisional versus Focal OSTial Stenting for Isolated Ostial Disease Occurring in Coronary Bifurcations (The PROST Trial)–Rationale and Design},
journal = {Heart, Lung and Circulation},
year = {2026},
doi = {10.1016/j.hlc.2026.09.010}
}
EUVIMED